Clinical trial · Interventional
Combination Chemotherapy in Treating Patients With Burkitt's Lymphoma or Burkitt's Leukemia
A Clinicopathological Study In Burkitts's And Burkitt-Like Non-Hodgkin's Lymphoma
NCT00040690CI-TRIAL-00013192completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients who have Burkitt's lymphoma or Burkitt's leukemia.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
Interventions
Interventions (10)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| cyclophosphamide | Drug | Cyclophosphamide | ALIAS |
| cytarabine | Drug | Cytarabine | ALIAS |
| doxorubicin hydrochloride | Drug | Doxorubicin | ALIAS |
| etoposide | Drug | Etoposide | ALIAS |
| filgrastim | Biological | Filgrastim | ALIAS |
| ifosfamide | Drug | Ifosfamide | ALIAS |
| leucovorin calcium | Drug | Leucovorin | ALIAS |
| methotrexate | Drug | Methotrexate | ALIAS |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Progression-free survival
Secondary outcomes (1)
- measure
- Survival time
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 16 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS: * Diagnosis of diffuse B-cell lymphoma in a nodal or an extranodal site * CD20 and CD79 positive * 100% expression of Ki67 (MIB1) in all of the tumor cells OR * Diagnosis of bone marrow replacement/leukemia comprising mature B-cell lymphoma * sIg and CD19 positive * CD34 and Tdt negative * Patients in the low-risk group must meet at least 3 of the following criteria: * Normal lactate dehydrogenase (LDH) level * WHO performance status 0-1 * Ann Arbor stage I or II * No more than 1 extranodal site (e.g., bone marrow, gastrointestinal tract, or CNS) * Patients in the high-risk group must meet at least 2 of the following criteria: * Raised LDH level * WHO performance status 2-4 * Ann Arbor stage III or IV * More than 1 extranodal site PATIENT CHARACTERISTICS: Age: * 16 and over Performance status: * See Disease Characteristics Life expectancy: * Not specified Hematopoietic: * See Disease Characteristics Hepatic: * See Disease Characteristics Renal: * Not specified Other: * No mental or physical status that would preclude study * No other disease or prior malignancy that would preclude study * HIV negative * Not pregnant * Negative pregnancy test * Fertile patients must use effective contraception PRIOR CONCURRENT THERAPY: Biologic therapy: * Not specified Chemotherapy: * No prior chemotherapy except 1 course of preinduction chemotherapy (e.g., CHOP \[cyclophosphamide, doxorubicin, vincristine, and prednisone\] or a related regimen) Endocrine therapy: * Not specified Radiotherapy: * No prior radiotherapy Surgery: * Not specified
References
Publications (1)
- RESULTMead GM, Barrans SL, Qian W, Walewski J, Radford JA, Wolf M, Clawson SM, Stenning SP, Yule CL, Jack AS; UK National Cancer Research Institute Lymphoma Clinical Studies Group; Australasian Leukaemia and Lymphoma Group. A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial). Blood. 2008 Sep 15;112(6):2248-60. doi: 10.1182/blood-2008-03-145128. Epub 2008 Jul 8. PMID 18612102